If so, we are prepared. We recently expanded our lab space, now home to our newest acquisition: the Orbitrap Exploris 240 LC-MS.
LCMS (Liquid Chromatography Mass Spectrometry) is rapidly emerging as a preferred technology for Multiple-Attribute Analysis (MAA), especially for complex biologics. By consolidating into a single, information-rich run what previously required multiple chromatographic methods (RP, IEX, HIC, etc.), LC-MS provides detailed molecular insights, enabling monitoring of critical quality attributes.
A trend today, a potential regulatory standard tomorrow? ProJect Pharmaceutics is already leading the way with next-generation technology on board!
ProJect Pharmaceutics is a CRO specialized in formulation and lyophilization process development for injectable drug products. Our newest team member, the Orbitrap Exploris 240 LC-MS (by Thermo Fisher https://documents.thermofisher.com/TFS-Assets/CMD/brochures/br-73410-ms-orbitrap-exploris-240-br73410-en.pdf), has moved into our expanded laboratory space, enabling next-level analytics for formulation and process development of injectable drug products, such as:
- mAb and ADC characterization
- Native DAR determination by SEC-MS
- Drug-load-distribution by PepMap
- Detection of degradation (fragments, side chain modifications, hydrolysis)
- Analysis of mAb glycosylation
- Impurity analysis (e.g. HCP)
Partner with us to unlock faster, deeper, and more precise analytical insights.
